Glucobay

Successful Bayer HealthCare participation in the European Society of Cardiology Congress 2005

		The recent European Society of Cardiology (ESC) congress in Stockholm, Sweden, was a great success for Bayer HealthCare, with a very well-attended satellite symposium. Professor Lars Ryden co-chaired an exciting case-study-based programme The cardiovascular disease prevention map - a multiroute approach. Specialists from different fields in cardiovascular disease (CVD) discussed the evidence for benefits of multiple risk assessment and management strategies, focusing on integrated therapy with Adalat, Aspirin and Glucobay. Despite competition from 16 other satellites running at the same time, the Bayer CV Risk Management satellite was attended by around 270 delegates.

It has been discussed which contribution each drug makes to the management of the other risk factors and what treatment regimen each of the speakers would recommend. The importance of optimizing treatment regimens, but also the need for tailored combined strategies to ensure the patient will have the best possible outcome have been highlighted. As always, the Bayer Cardiovascular Risk Products booth had a continuous stream of visitors. Delegates were drawn in by the latest Adalat/ACTION publications, the Aspirin Women's Health Study booklet and Glucobay papers highlighting acarbose as first-line therapy for type 2 diabetes offering additional benefits in CV risk patients. The program is available as download here (pdf, 504 KB).